Oral contraceptive use as teenager linked to depression as an adult, study says
August 29, 2019Research and Development MDD, depression, hormones, oral contraceptives, psychiatry, psychology
Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a …
Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder
August 28, 2019Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris
Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
Sea snail chemical could be used as preventative treatment for bowel cancer, study shows
August 28, 2019Research and Development Australia, Cancer, bowel cancer, pharma, research
A chemical produced by Australian sea snails is showing promise as a potential treatment for cancer, according to researchers from …
Johns Hopkins researchers to study psilocybin as a treatment for anorexia in Phase 1 trial
August 28, 2019Research and Development Johns Hopkins, Magic mushrooms, anorexia, mushrooms, pharma, psilocybin
Scientists at Johns Hopkins University are exploring psilocybin as a potential treatment for chronic anorexia nervosa. Researchers at Johns Hopkins …
Over half of all US/EU regulator warnings issued to Indian and Chinese manufacturers, report finds
August 28, 2019Manufacturing and Production, Research and Development China, India, MHRA, UK, manufacturing, pharma
Concerns have been raised concerning the integrity of the global supply chain after a report from The Pharmaceutical Journal revealed …
Sacklers could give up Purdue Pharma and settle 2,000 lawsuits for $10-12 billion, proposal says
August 28, 2019Research and Development OxyContin, Purdue Pharma, Sackler family, opioid crisis, opioids, pharma
The Sackler family are offering to settle more than 2,000 opioid crisis lawsuits for between $10-12 billion, according to NBC. …
Working Life: Linda Armstrong, Global Head, Respiratory Development Unit at Novartis
August 27, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Working Life, feature, pharma
Linda Armstrong, Global Head, Respiratory Development Unit at Novartis.
FibroGen rocked by unexpected death of CEO Thomas B Neff
August 27, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, fibrogen, pharma
In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, its Chief Executive Officer and …
NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy
August 27, 2019Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
The Royal College of Obstetricians and Gynaecologists (RCOG) call for action over shortages of hormone replacement therapy (HRT)
August 27, 2019Manufacturing and Production HRT, UK, healthcare, pharma, shortages
The Royal College of Obstetricians and Gynaecologists (RCOG) have called for action from government and pharmaceutical companies to adress ongoing …
J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says
August 27, 2019Manufacturing and Production J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, opioids, pharma
A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in …
Four perspectives from life sciences companies on multichannel engagement
August 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma
By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
Japan approves Genmab’s Darzalex in newly diagnosed multiple myeloma
August 22, 2019Sales and Marketing
Genmab has secured a new approval for its CD38 monoclonal antibody Darzalex (daratumumab), this time in Japan for the treatment …
NICE Chief Sir Andrew Dillon to step down in 2020
August 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK pharma, UK< pharma
It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible …
HHS to fund production of MSD’s Ebola vaccine V920
August 22, 2019Manufacturing and Production Ebola, HHS, MSD, Vaccine, pharma
The US Department of Health and Human Services (HHS) has said it will fund the production of MSD’s investigational Ebola …
Gilead challenges Government over patents on preventative HIV drug Truvada
August 22, 2019Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents
Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
GSK’s two drug HIV regimen effective when administered every two months
August 22, 2019Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression
GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …
NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation
August 21, 2019Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma
AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
Teva launch generic version of EpiPen for children
August 21, 2019Research and Development Mylan, Teva, allergies, children, epipen, pharma
A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
